Last reviewed · How we verify
TRIENTINE HYDROCHLORIDE
At a glance
| Generic name | TRIENTINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
Common side effects
- Iron deficiency
- Systemic lupus erythematosus
- Dystonia
- Muscular spasm
- Myasthenia gravis
- Heartburn
- Epigastric pain and tenderness
- Thickening, fissuring and flaking of the skin
- Hypochromic microcytic anemia
- Acute gastritis
- Aphthoid ulcers
- Abdominal pain
Serious adverse events
- Rhabdomyolysis
Key clinical trials
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. (PHASE3)
- Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
- Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
- Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride (PHASE2)
- Real World Evidence Study in Subjects With Wilson's Disease
- The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy (PHASE2)
- Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). (PHASE1)
- International Wilson's Disease Patient Registry (iWilson Registry)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRIENTINE HYDROCHLORIDE CI brief — competitive landscape report
- TRIENTINE HYDROCHLORIDE updates RSS · CI watch RSS